secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001790340-24-000064
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports Q2 net loss $14.1M; Fast Track for IMM-1-104; initial Phase 2 data expected 2H 2024
--------------------------------------------------------------------------------

- Net loss $14.1M ($0.47/share) vs $12.2M ($0.43) in Q2 2023.
- Cash $59.7M as of June 30, 2024; expected cash runway into 2H 2025.
- FDA granted Fast Track designation for IMM-1-104 in first-line pancreatic cancer.
- Initial data from multiple arms of IMM-1-104 Phase 2a trial expected in 2H 2024.
- Initial PK/PD/safety data for IMM-6-415 Phase 1 expected in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000064/0001790340-24-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000064/imrx-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001790340-24-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer